19 related articles for article (PubMed ID: 14550813)
1. Discordance Between the Predicted Versus the Actually Recognized CD8+ T Cell Epitopes of HCMV pp65 Antigen and Aleatory Epitope Dominance.
Lehmann AA; Zhang T; Reche PA; Lehmann PV
Front Immunol; 2020; 11():618428. PubMed ID: 33633736
[TBL] [Abstract][Full Text] [Related]
2. Overall avidity declines in TCR repertoires during latent CMV but not EBV infection.
Couturaud B; Doix B; Carretero-Iglesia L; Allard M; Pradervand S; Hebeisen M; Rufer N
Front Immunol; 2023; 14():1293090. PubMed ID: 38053994
[TBL] [Abstract][Full Text] [Related]
3. Multimer technologies for detection and adoptive transfer of antigen-specific T cells.
Casalegno-Garduño R; Schmitt A; Yao J; Wang X; Xu X; Freund M; Schmitt M
Cancer Immunol Immunother; 2010 Feb; 59(2):195-202. PubMed ID: 19847424
[TBL] [Abstract][Full Text] [Related]
4. The contributions of mass spectrometry to understanding of immune recognition by T lymphocytes.
Engelhard VH
Int J Mass Spectrom; 2007 Jan; 259(1-3):32-39. PubMed ID: 18167512
[TBL] [Abstract][Full Text] [Related]
5. Highly protective in vivo function of cytomegalovirus IE1 epitope-specific memory CD8 T cells purified by T-cell receptor-based cell sorting.
Pahl-Seibert MF; Juelch M; Podlech J; Thomas D; Deegen P; Reddehase MJ; Holtappels R
J Virol; 2005 May; 79(9):5400-13. PubMed ID: 15827154
[TBL] [Abstract][Full Text] [Related]
6. Use of a lentiviral vector encoding a HCMV-chimeric IE1-pp65 protein for epitope identification in HLA-Transgenic mice and for ex vivo stimulation and expansion of CD8(+) cytotoxic T cells from human peripheral blood cells.
Rohrlich PS; Cardinaud S; Lulè J; Montero-Julian FA; Prodhomme V; Firat H; Davignon JL; Perret E; Monseaux S; Necker A; Michelson S; Lemonnier FA; Charneau P; Davrinche C
Hum Immunol; 2004 May; 65(5):514-22. PubMed ID: 15172452
[TBL] [Abstract][Full Text] [Related]
7. Ex vivo stimulation and expansion of both CD4(+) and CD8(+) T cells from peripheral blood mononuclear cells of human cytomegalovirus-seropositive blood donors by using a soluble recombinant chimeric protein, IE1-pp65.
Vaz-Santiago J; Lulé J; Rohrlich P; Jacquier C; Gibert N; Le Roy E; Betbeder D; Davignon JL; Davrinche C
J Virol; 2001 Sep; 75(17):7840-7. PubMed ID: 11483727
[TBL] [Abstract][Full Text] [Related]
8. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL.
Wills MR; Carmichael AJ; Mynard K; Jin X; Weekes MP; Plachter B; Sissons JG
J Virol; 1996 Nov; 70(11):7569-79. PubMed ID: 8892876
[TBL] [Abstract][Full Text] [Related]
9. Sensitive detection of human cytomegalovirus peptide-specific cytotoxic T-lymphocyte responses by interferon-gamma-enzyme-linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation.
Hebart H; Daginik S; Stevanovic S; Grigoleit U; Dobler A; Baur M; Rauser G; Sinzger C; Jahn G; Loeffler J; Kanz L; Rammensee HG; Einsele H
Blood; 2002 May; 99(10):3830-7. PubMed ID: 11986243
[TBL] [Abstract][Full Text] [Related]
10. Human cytomegalovirus proteins pp65 and immediate early protein 1 are common targets for CD8+ T cell responses in children with congenital or postnatal human cytomegalovirus infection.
Gibson L; Piccinini G; Lilleri D; Revello MG; Wang Z; Markel S; Diamond DJ; Luzuriaga K
J Immunol; 2004 Feb; 172(4):2256-64. PubMed ID: 14764694
[TBL] [Abstract][Full Text] [Related]
11. A CTL epitope from human cytomegalovirus IE1 defined by combining prediction of HLA binding and proteasomal processing is the target of dominant immune responses in patients after allogeneic stem cell transplantation.
Hebart H; Rauser G; Stevanovic S; Haenle C; Nussbaum AK; Meisner C; Bissinger AL; Tenzer S; Jahn G; Loeffler J; Rammensee HG; Schild H; Einsele H
Exp Hematol; 2003 Oct; 31(10):966-73. PubMed ID: 14550813
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
